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Abstract
Introduction: Viscosupplementation with hyaluronic acid (HA) of osteoarthritic (OA) knee joints has a well-
established positive effect on clinical symptoms. This effect, however, is only temporary and the working mechanism
of HA injections is not clear. It was suggested that HA might have disease modifying properties because of its
beneficial effect on cartilage sulphated glycosaminoglycan (sGAG) content. Delayed gadolinium-enhanced MRI of
cartilage (dGEMRIC) is a highly reproducible, non-invasive surrogate measure for sGAG content and hence
composition of cartilage. The aim of this study was to assess whether improvement in cartilage structural composition
is detected using dGEMRIC 14 weeks after 3 weekly injections with HA in patients with early-stage knee OA.
Methods: In 20 early-stage knee OA patients (KLG I-II), 3D dGEMRIC at 3T was acquired before and 14 weeks after
3 weekly injections with HA. To evaluate patient symptoms, the knee injury and osteoarthritis outcome score (KOOS)
and a numeric rating scale (NRS) for pain were recorded. To evaluate cartilage composition, six cartilage regions in
the knee were analyzed on dGEMRIC. Outcomes of dGEMRIC, KOOS and NRS before and after HA were compared
using paired t-testing. Since we performed multiple t-tests, we applied a Bonferroni-Holm correction to determine
statistical significance for these analyses.
Results: All KOOS subscales (‘pain’, ‘symptoms’, ‘daily activities’, ‘sports’ and ’quality of life’) and the NRS pain
improved significantly 14 weeks after Viscosupplementation with HA. Outcomes of dGEMRIC did not change
significantly after HA compared to baseline in any of the cartilage regions analyzed in the knee.
Conclusions: Our results confirm previous findings reported in the literature, showing persisting improvement in
symptomatic outcome measures in early-stage knee OA patients 14 weeks after Viscosupplementation. Outcomes of
dGEMRIC, however, did not change after Viscosupplementation, indicating no change in cartilage structural
composition as an explanation for the improvement of clinical symptoms.
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Introduction
Knee osteoarthritis (OA) is the most common joint disease in
middle-aged and elderly, causing serious morbidity and large
socio-economic impact [1-3]. The current treatment strategies
for OA, however, are limited and end-stage OA is treated with
invasive joint replacement surgery. An important drawback of
this surgery is the limited durability of joint prostheses and
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hence the need for revision if implanted in relatively young
patients. Therefore, OA research focuses on the development
of disease modifying osteoarthritic drugs (DMOADs) which may
allow treatment before OA reaches its end-stage [4].
Hyaluronic acid (HA) improves the viscoelastic properties of
synovial fluid [5] and intra-articular injections with HA are
nowadays frequently used as a viscosupplement in the
treatment of knee OA [6]. Recently, a Cochrane review on the
efficacy of viscosupplementation with HA in knee OA reported
significantly good, but temporary clinical effects on pain,
function and patient global assessment with the highest effect
sizes between 5 and 14 weeks after viscosupplementation if
high-molecular-weight HA derivatives are used [7].
The working mechanism of HA injections, however, is not yet
clear. It has been suggested that viscosupplementation, in
addition to symptomatic benefits, may also have disease
modifying properties in OA [8,9]. As a possible pathway for
disease modification, previous in-vitro research showed that
HA has a beneficial effect on chondrocytes that are stimulated
to produce proteoglycans (PG) [10-13]. PGs, which mainly
consist of sulphated glycosaminoglycan (sGAG), are one of the
main components of the extracellular matrix of articular
cartilage [14,15]. It is known that PGs are depleted in the early
stages of OA, long before cartilage degeneration is visible as
joint space narrowing on radiography [16]. Therefore,
radiography is considered an inappropriate imaging tool for
detection and follow-up of early-stage OA in clinical research
[17]. Moreover, common magnetic resonance imaging (MRI)
techniques that assess cartilage morphology alterations have
also shown to be insensitive to detect subtle changes in
biochemical cartilage composition [18,19]. In order to diagnose
OA in early-stage disease and detect intervention-caused
biochemical changes sensitively during follow up, sophisticated
MRI techniques have been developed during the last decade.
These techniques provide a quantitative measure of the
amount of sGAG, collagen or sodium of articular cartilage and
therefore are a measure for cartilage structural composition
[20,21].
An example of such a MRI technique to measure cartilage
structural composition is delayed gadolinium-enhanced MRI of
cartilage (dGEMRIC). The technique uses the inverse relation
between a negatively charged contrast agent and the sGAG
content of cartilage and therefore provides an indirect
quantitative outcome measure for cartilage sGAG content
[22,23]. Because of its ability to serve as a non-invasive
indirect measure for cartilage structural composition, dGEMRIC
has become a standard for assessment of articular cartilage
sGAG content in OA research. Recently, dGEMRIC was also
shown to be a highly reproducible surrogate outcome measure
of cartilage sGAG content over time in early-stage OA knees
[24]. Since other direct outcome measures such as cartilage
biopsies are usually not ethically accepted, dGEMRIC is
considered a suitable tool to non-invasively evaluate potential
structure modification in terms of sGAG content improvement
in articular cartilage.
Based on the aforementioned literature, we hypothesize that
the improvement in clinical symptoms after HA injections will be
corroborated by an improvement in sGAG content in the
articular cartilage. Therefore, the aim of this study was to
assess whether improvement in structural composition of
cartilage is detected using dGEMRIC 14 weeks after 3 weekly
injections with HA in patients with early-stage knee OA.
Materials and Methods
Study design and participants
For this prospective follow-up study conducted between
March and September 2011, we recruited and included 20
participants with early-stage OA of the knee from the outpatient
clinic of the Department of Orthopedic Surgery of our
institution. This sample size was based on an expected
difference in T1 relaxation time of at least 95 ms which has
been shown to represent a clinically relevant improvement in
cartilage sGAG content as measured by 3D dGEMRIC of early-
stage OA knees acquired at 3.0 Tesla [24], a standard
deviation of 100 ms of T1 relaxation times with 3D dGEMRIC of
early-stage OA knees acquired at 3.0 Tesla, an α of 0.008
(corrected for multiple testing using Bonferroni-Holm method:
see statistical analysis), a power of 0.8 and a maximum lost to
follow-up of 10% of the included participants.
We were not able to include a control group in this study,
because this was considered unethical by the Institutional
Review Board (IRB). However, this was not a problem because
it was not our aim to assess the potential clinical improvement
of HA injections compared to a placebo or non-treated
participant group. Such studies have already been performed
and have shown a clinical improvement of HA injections
compared to placebo [6,7]. Moreover, OA is generally a slow
progressing disease in which no significant change in
dGEMRIC outcomes was found at 14, 24 and 48 weeks follow-
up compared to baseline in the control groups (n=15 and n=10
respectively) of two randomized controlled trials consisting of
mild to moderate knee OA patients [25,26]. Thus, the absence
of a control group was not considered a limitation to address
our study aim, i.e. the assessment of potential sGAG increase
in an index group treated with viscosupplementation. Based on
the aforementioned results we expect that dGEMRIC would
have detected minor and non-significant changes in sGAG
content of the cartilage in a control group of non-treated early-
stage OA patients between the baseline and follow-up
measurement 14 weeks later.
The inclusion criteria for our study were: participants age >
18 years, knee pain duration > 3 months, severity of knee pain
> 2 out of 10 on a numeric rating scale (NRS) for pain (score
from 0 - 10: the higher the score, the more knee pain) [27], and
radiographic knee OA with a Kellgren and Lawrence grade of 1
or 2 [28]. Exclusion criteria were: viscosupplementation in the
index knee within the last year, glucocorticoid injection(s) in the
index knee within the last three months, absolute contra-
indications to undergo MRI, renal insufficiency (glomerular
filtration rate < 60 ml/min), a history of contrast medium allergy,
significant co-morbidities in the lower extremity containing the
index knee joint, knee surgery in the index knee within the last
year or knee surgery scheduled in the index knee within the
next half year.
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Written informed consent was obtained from all participants
and the study was approved by the IRB (Medical Ethical
committee of the Erasmus MC, protocol number
MEC-2010-088).
Study protocol
Within two weeks before viscosupplementation of the index
knee, a baseline dGEMRIC examination and routine MRI
sequences of the index knee were acquired in all participants.
Participants were also asked to rate their knee complaints on
the Knee injury and Osteoarthritis Outcome Score (KOOS)
[29]. The KOOS consists of 5 subscales (score from 0-100, the
lower the score, the more knee symptoms in that subscale):
‘pain’, ‘symptoms’, ‘activities of daily living’ (ADL), ‘sport and
function’ (sport), and ‘knee-related quality of life’ (QoL) and was
validated in Dutch for early-stage OA patients by De Groot et
al. in 2008 [30]. In addition to the KOOS, all participants were
asked to rate their knee pain on a NRS for pain. The NRS is a
numeric rating scale for pain (score from 0 - 10: the higher the
score, the more knee pain) comparable with the visual
analogue scale for pain, but is easier to use for patients
because pain can be expressed as a number [27].
After obtaining the baseline measurements,
viscosupplementation was performed using an intra-articular
injection with Hylan G-F 20 (Synvisc®, Genzyme Corp,
Cambridge, USA). With a time interval of one week between
the injections, three injections with Hylan G-F 20 were provided
by an experienced orthopedic surgeon according to a
standardized protocol using a superolateral approach [31].
Follow-up measurements (dGEMRIC examination and
routine MRI sequences, KOOS questionnaire, and NRS for
pain) were obtained 14 weeks after viscosupplementation with
HA. We chose a 14 weeks interval between
viscosupplementation and follow-up measurements because
the highest clinical effect sizes of intra-articular injections with
HA have been reported between 5 and 14 weeks after
treatment [7].
Acquisition of dGEMRIC and routine MRI sequences
Before MR imaging, a double dose (0.2 mmol/kg) of
gadopentetate dimeglumine (Magnevist®, Bayer Schering AG,
Berlin, Germany) was injected intravenously based on the
participants’ weight [32]. For the follow-up dGEMRIC
examination, we used the same amount of contrast agent as
we used for the baseline dGEMRIC examination. This way, the
outcomes of the follow-up dGEMRIC are not biased by the
participants’ body mass index (BMI) [33]. After contrast
administration, the participants were asked to cycle for 10
minutes on a home trainer at constant speed to promote
contrast distribution into and throughout the knee and the
articular cartilage [34]. After cycling and a delay of 80 minutes,
the dGEMRIC images were acquired.
MR imaging was performed on a 3.0 Tesla MRI scanner
(Discovery MR750, General Electric Healthcare, Milwaukee,
WI, USA) using a custom made 3 channel knee coil (Flick
Engineering Solutions B.V., Winterswijk, The Netherlands)
[24,35]. We used a three-dimensional (3D) dGEMRIC protocol
which was acquired in the sagittal plane and was previously
published by McKenzie et al. [36]. The dGEMRIC protocol
consisted of an inversion recovery fast spoiled gradient-echo
sequence, which was acquired for five times with different
inversion times (TI=2100; 800; 400; 200 and 100 ms). The
other scanning parameters were constant during scanning:
matrix 256 x 232 pixels; field of view 150 mm; slice thickness 3
mm; flip angle 15°; echo time 1.5 ms and repetition time (TR)
3.9 ms, pixel bandwidth 488 Hz/voxel and number of averages
1. The total acquisition time was approximately 14 minutes,
resulting in 36 sagittal MR images with complete coverage of
the knee joint.
In addition to dGEMRIC scans, three routine sequences
consisting of a fast spin echo (FSE) proton density weighted
sequence (sagittal and axial plane) and a coronal FSE T2-
weighted sequence with fat suppression were acquired to allow
morphological evaluation of the cartilage and incidental findings
(e.g., chondroid tumors, bone tumors, etc.) in the knee. The
scanning time of the additional sequences was approximately
11 minutes, resulting in a total scanning time of approximately
25 minutes for the entire MRI protocol.
dGEMRIC analysis
Using Matlab (R2011a, The MathWorks, Natick, MA, USA),
three cartilage regions of interest (ROIs) were drawn manually
on three consecutive images through the lateral and medial
tibiofemoral joint (central image and one adjacent image on
each side) by a researcher with a medical degree and 4 years
of experience in this research field (JvT). These qualifications
were considered sufficient, especially since Tiderius and
colleagues showed that the experience of the investigator does
not affect the variability of manual ROI selection in dGEMRIC
[37].
ROI selection was standardized and based on the scheme
suggested by Eckstein et al. [38]. These anatomical landmark
based ROIs were drawn on the TI=2100 ms images of the first
dGEMRIC examination and consisted of the weight-bearing
cartilage of the femoral condyles (wbFC), the posterior non
weight-bearing cartilage of the femoral condyles (pFC) and the
weight-bearing cartilage of the tibial plateaus (wbTP) (Figure
1).
During acquisition of dGEMRIC, patient motion might occur.
This patient motion may cause errors and imprecision in the
outcomes of dGEMRIC, but image registration can correct for
patient motion within dGEMRIC [39]. To correct for patient
motion, we used an in-house developed registration and T1-
fitting algorithm (Software for Post-processing And Registration
of Cartilage of the Knee: SPARCK) that was previously
published [35]. In the registration part of the algorithm, first all
images with different TI values were aligned to the TI=2100 ms
images. The femoral condyle and tibial plateau were registered
separately. The images were registered using a 3D rigid
transformation model by maximization of localized mutual
information. To minimize the blurring of the registered images,
cubic interpolation was used [40]. The registration was
performed separately for the baseline and follow-up dGEMRIC
acquisitions. All registrations were performed using open
source registration software (Elastix, http://elastix.isi.uu.nl/)
[41]. After the first step, the follow-up examination is registered
No Change in Cartilage Composition after HA
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to the baseline examination based on the images with TI=2100
ms, the other TI images of the follow-up acquisition are
transformed accordingly. Automated registration of baseline
and follow-up scans eliminates subjective visual slice matching
and also eliminates the need to manually outline the cartilage
ROIs in the follow-up scan.
For the registered dGEMRIC baseline and follow-up
datasets, T1 maps were estimated using a maximum likelihood
fit [35]. After injection with Magnevist®, cartilage regions with
long T1 relaxation time have relatively high sGAG content
compared to cartilage regions with short T1 relaxation time
which indicates reduced sGAG content [23,34]. All possible
partial volume pixels for the cortical bone in the cartilage ROIs
were automatically excluded for the ROIs using a patient
specific bone-cartilage threshold which removed bone pixels
for the manually drawn ROI before calculating the T1 relaxation
time in all ROIs. Finally, in all cartilage ROIs, the weighted T1
relaxation time per ROI was calculated, where the estimated
T1 relaxation time of each voxel was weighted by the reciprocal
of its uncertainty. The uncertainty was measured by the square
root of the Cramér-Rao Lower Bound, which gives a lower
bound for the standard deviation of the estimated T1
[42-44]. Residual misalignment of the T1-weighted images,
especially at tissue boundaries, results in biologically
implausible values of T1, often associated with great
uncertainty. Using the weighted mean, these implausible T1
relaxation times will not heavily influence the calculated mean
T1 relaxation times in the determined cartilage ROIs [35].
The weighted T1 relaxation times for each anatomical
cartilage ROI were averaged over the three consecutive MR
images. This way we used the available 3D information instead
of only using a single MR slice (2D analysis) in both the medial
and lateral compartment of the knee as in most previous
studies using dGEMRIC. Thus, for each patient in each
dGEMRIC examination, six weighted average T1 relaxation
times from six anatomical cartilage ROIs were obtained.
Morphological cartilage analysis
On the routine MRI sequences, the articular cartilage was
scored for cartilage defects according to the MRI Osteoarthritis
Knee Score (MOAKS) as described by Hunter et al. [45]. Both
Figure 1.  Cartilage regions analyzed using dGEMRIC.  Central sagittal MR image through the lateral tibiofemoral joint. The three
anatomical cartilage ROIs which were drawn and analyzed on three consecutive images in each compartment of the tibiofemoral
joint are shown. wbFC (green): weight-bearing cartilage of the femoral condyle. pFC (yellow): posterior non weight-bearing cartilage
of the femoral condyle. wbTP (red): weight-bearing cartilage of the tibial plateau.
doi: 10.1371/journal.pone.0079785.g001
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the baseline and the follow-up MRI were read by an
experienced musculoskeletal radiologist (EO).
Statistical analysis
We tested our data for normality and equal variance using
the Kolmogorov-Smirnov and Levene’s test. The outcomes of
these tests showed normality and equal variance of our data.
We used paired t-tests to compare the outcomes of dGEMRIC
in each anatomically defined cartilage ROI between follow-up
and baseline. The same tests were used to compare the
outcomes of each KOOS subscale and the NRS for pain 14
weeks after HA injections with the baseline outcomes. Since
six cartilage ROIs and six subscales of questionnaires (KOOS
and NRS were analyzed together) were compared between
baseline and follow-up using six paired t-tests, we applied a
Bonferroni-Holm correction [46] to define statistically significant
p-values for these analyses. We present both the crude, as
well as the adjusted p-values to determine whether a particular
test result is statistically significant after Holm’s adjustment of
the p-values [47]. P-values of < 0.05 were considered
statistically significant. All analyses were performed using
SPSS 20.0 (SPSS Inc., Chicago, IL, USA).
Results
Participants
We included 20 participants (eight female) with early-stage
OA of the knee (seven left knee joints). Their mean age at the
time of inclusion was 48 ± 11 years and their mean BMI was 29
± 5 kg/m2.
On radiography, 11 participants had early-stage OA in the
medial tibiofemoral compartment. Two participants only had
OA in the lateral tibiofemoral and 7 participants had OA in both
knee compartments. No incidental findings were observed on
routine MRI.
All baseline measurements were obtained two weeks (range
8 - 16 days) before viscosupplementation of the index knee
with HA. The mean time between the first and second and
second and third HA injection was 7 ± 0 days for all
participants. All follow-up measurements were obtained 14
weeks (range 14 - 16 weeks) after viscosupplementation. All
included patients completed both the baseline and the follow-
up measurements.
dGEMRIC outcomes
At baseline, mean T1 relaxation times ranged from 461 to
491 ms in the three different cartilage regions in the medial
tibiofemoral compartment. The mean T1 relaxation times in the
lateral compartment were higher than those in the medial
compartment and ranged from 475 to 581 ms in the different
regions (p-value = 0.0006) (Table 1). At 14 weeks follow-up,
the mean T1 relaxation times in the medial compartment of the
knee ranged from 456 to 520 ms and in the lateral
compartment from 498 to 579 (p-value = 0.04) (Table 1).
We did not observe a statistically significant change in T1
relaxation times in any of the analyzed cartilage regions
between the baseline measurements and the follow-up
measurements (all adjusted p-values > 0.05) (Table 1). In
Figure 2, an example of a participant without change in
cartilage T1 relaxation times and hence cartilage composition
after HA injections is shown.
In two ROIs (wbFC and wbTP) in the lateral knee
compartment and one ROI in the medial compartment (wbFC),
a trend towards a decrease in indirectly measured cartilage
sGAG content in terms of lower mean T1 relaxation times was
observed (Figure 3). In one ROI in the lateral compartment
(pFC) and in two ROIs in the medial compartment (pFC and
wbTP), mean T1 relaxation times after viscosupplementation
showed a trend towards improvement compared to baseline
(Figure 3). These trends were, however, neither statistically
significant, nor exceeded a previously determined threshold of
95 ms for clinically relevant improvement in cartilage sGAG
content measured using dGEMRIC [24].
Differences in T1 relaxation times at follow-up reached this
threshold only in seven participants in a single cartilage ROI (3
times lateral pFC, 3 times medial pFC and 1 time lateral wbTP:
data for each individual participant not shown). In the other
ROIs in these participants, this 95 ms threshold was not
reached. In the remaining 13 participants, the threshold for T1
improvement was not reached in any of the analyzed cartilage
ROIs.


















compartment     
Weight-bearing
femoral
512 (478 - 546)
ms
510 (482 -
538) ms 0.89 0.89
Posterior femoral 475 (434 - 516)ms
487 (450 -
524) ms 0.42 > 0.99
Weight-bearing
tibia
581 (529 - 633)
ms
579 (526 -
630) ms 0.85 > 0.99
Medial tibiofemoral
compartment     
Weight-bearing
femoral
461 (417 - 505)
ms
456 (411 -
500) ms 0.64 > 0.99
Posterior femoral 488 (432 - 544)ms
520 (470 -
569) ms 0.04 0.24
Weight-bearing
tibia
491 (441 - 541)
ms
512 (466 -
558) ms 0.09 0.45
Mean T1 relaxation times with 95% confidence interval for the mean in
milliseconds at baseline and at 14 weeks follow-up after HA injections (n=20 for
each anatomical cartilage ROI). 95% CI: 95% confidence interval.
doi: 10.1371/journal.pone.0079785.t001
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Morphological cartilage analysis
On the routine MRI sequences, a total of 240 cartilage
regions were assessed for cartilage lesions using the MOAKS
criteria. A total of 21 regions were diagnosed with a cartilage
lesion (6 in the lateral and 15 in the medial compartment) and
219 regions showed normal cartilage morphology. Eight full
thickness cartilage defects were observed at baseline in 3
participants. Thirteen partial cartilage lesions were observed in
11 participants. All cartilage lesions had a size of either <10%
or 10-75% of the region of cartilage surface area. No
progression in any partial and full thickness size or progression
from partial to full thickness cartilage lesions were observed at
14 weeks follow-up.
KOOS and NRS outcomes
All KOOS subscales, ‘pain’ (mean at baseline: 48, mean at
follow-up: 66, crude p-value = 0.0003, adjusted p-value =
0.002), ‘symptoms’ (mean at baseline: 49, mean at follow-up:
56, crude p-value = 0.03, adjusted p-value = 0.03), ‘ADL’
(mean at baseline: 55, mean at follow-up: 72, crude p-value =
0.0007, adjusted p-value = 0.003), ‘sports’ (mean at baseline:
20, mean at follow-up: 35, crude p-value = 0.004, adjusted p-
value = 0.01), and ‘QoL’ (mean at baseline: 28, mean at follow-
up: 38, crude p-value = 0.01, adjusted p-value = 0.02),
improved significantly 14 weeks after HA injections in the knee
(Figure 4). The mean NRS pain score at baseline was 7 and
improved significantly (crude p-value < 0.0001, adjusted p-
value < 0.0001) to a mean of 4 14 weeks after HA injections
(Figure 4).
Discussion
Because of the lack of established DMOADs for early-stage
knee OA, intra-articular viscosupplementation with HA has
become a frequently used treatment for reducing symptoms
and pain in early-stage knee OA [6,7]. Since it was suggested
in previous in-vitro research that HA injections might also have
disease modifying properties by increasing cartilage sGAG
content [10-13], the aim of this study was to assess whether
improvement in cartilage structural composition is detected
using dGEMRIC 14 weeks after 3 weekly injections with HA in
patients with early-stage knee OA.
Outcomes of dGEMRIC in the medial compartment of the
knee were lower compared to the lateral compartment at
baseline, indicating more structural damage in the medial knee
compartment. T1 relaxation times in both knee compartments
were lower compared to previously published dGEMRIC T1
relaxation times acquired at 3.0 Tesla in healthy subjects
[36,48,49], indicating sGAG loss from the cartilage in our early-
stage OA patients. The outcomes of dGEMRIC are consistent
with radiographic findings and our morphological cartilage
assessment on MRI with MOAKS and reflect the early-stage
OA population in which sGAG loss occurs before
morphological changes are detectable on radiography or MRI
(e.g. using MOAKS). We observed early-stage OA in the
medial compartment of the knee in 18 of the 20 participants,
which is defined as mild to moderate osteophyte formation as
the only features on radiography, and only a few participants
with partial cartilage damage according to MOAKS, without
definite joint space narrowing or bone on bone contact which
are signs of advanced or end-stage OA. Based on these
Figure 2.  dGEMRIC color overlay representing cartilage sGAG content at baseline and follow-up.  Representative sagittal
central MR image through the medial tibiofemoral compartment of an early-stage OA knee before (A) and after (B)
viscosupplementation with HA. The T1 color map of the cartilage clearly shows a region with relatively lower T1 relaxation times
(grey arrows in A), indicating relatively lower sGAG content in the weight-bearing femoral cartilage before viscosupplementation (A).
After HA injections (B), however, the region with relatively low T1 relaxation times is still present (grey arrows in B).
doi: 10.1371/journal.pone.0079785.g002
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characteristics, we consider our study population suitable to
evaluate the potential structural effects of
viscosupplementation as a potential DMOAD, since this should
be tested in early stages of OA in which disease modification is
still possible [4].
At follow-up, 14 weeks after viscosupplementation with HA,
no statistically significant change in cartilage sGAG content
was detected on dGEMRIC in any of the analyzed anatomical
cartilage ROIs compared to the baseline measurements.
Outcomes of dGEMRIC showed a trend towards improvement
in three of the analyzed cartilage ROIs two of which were the
medial and lateral non-weight-bearing cartilage regions of the
femoral condyles. This is somewhat unexpected, as one would
expect an improvement in cartilage structural composition in
the weight-bearing femoral condyles and/or plateaus since
those ROIs had lower T1 relaxation times and hence more
structural damage at baseline. Moreover, the improvement in
T1 relaxation times did not exceed a previously determined
threshold of 95 ms which has been shown to represent a
clinically relevant improvement in cartilage sGAG content as
measured by 3D dGEMRIC of early-stage OA knees acquired
at 3.0 Tesla [24]. It may be that there are non-significant
changes between baseline and follow-up T1 relaxation times
which means that the measurements were not the same
between the two time points. However, we hypothesized that if
the reported clinical effect of viscosupplementation, confirmed
by our study, would act through an improvement of sGAG
Figure 3.  Differences between dGEMRIC T1 relaxation times at baseline and follow-up.  Bar graphs showing the differences
in dGEMRIC T1 relaxation times in each anatomical cartilage ROI at follow-up, 14 weeks after HA injections compared to baseline.
The bar represents the mean and the whiskers represent the 95% confidence interval for the mean. +95 ms: clinically relevant
threshold for improvement in cartilage sGAG content if a single patient is followed over time using dGEMRIC [24]. -85 ms: clinically
relevant threshold for impairment of cartilage sGAG content if a single patient is followed over time using dGEMRIC [24]. wbFC:
weight-bearing cartilage of the femoral condyle. pFC: posterior non weight-bearing cartilage of the femoral condyle. wbTP: weight-
bearing cartilage of the tibial plateau.
doi: 10.1371/journal.pone.0079785.g003
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content, this would have been detectable using dGEMRIC with
the sample size of our study.
We believe there are several possible explanations why we
did not observe an increase in cartilage sGAG content by
dGEMRIC 14 weeks after viscosupplementation of early-stage
OA knees. First, cartilage sGAG content and therefore
dGEMRIC outcomes might not improve after
viscosupplementation if the treatment does not have any
disease modifying effects on articular cartilage. Instead,
viscosupplementation may have a primary positive effect on
pain and other clinical symptoms of OA. This working
mechanism was suggested for HA injections in a recent OARSI
review by Zhang et al. in which the evidence for available
therapies in the treatment of hip and knee OA was re-evaluated
and discussed [50].
A second explanation why T1 relaxation times did not
increase is that viscosupplementation may slow down the
progression of OA by preventing the loss of sGAG content
rather than improving the sGAG content of cartilage (the latter
was our hypothesis in this study). This working mechanism of
HA was suggested in several in vitro studies [51-53], and is
supported by the results of recent animal and human studies in
which the structural efficacy of HA treatment over time was
compared to a control group (non-treatment and placebo) using
another quantitative MRI technique (T2 mapping) [54] and
cartilage thickness and volume measurements on MRI [55].
However, as it was considered unethical to include a control
group by the IRB, we could not compare the sGAG content 14
weeks after viscosupplementation with the sGAG content of
cartilage without viscosupplementation.
A third possible reason that T1 relaxation times may not
increase after HA injections is the detection limit and specificity
of dGEMRIC to detect (change) in sGAG content of articular
cartilage. Minimal changes in sGAG content of cartilage
following HA treatment may not be detected using dGEMRIC
T1 because, although the technique is highly reproducible in
knee OA [24], it is currently unknown to which extent minimal
change in sGAG content are detectable using dGEMRIC in
humans. dGEMRIC is an indirect measure for cartilage sGAG
content and there are no in vivo studies which investigated the
sensitivity and specificity of dGEMRIC to measure (small)
changes in sGAG content of the extracellular matrix of
cartilage. Other drawbacks of dGEMRIC are the long
acquisition protocol because of the delay between the contrast
administration and MR acquisition and the risk of nephrogenic
systemic fibrosis due to contrast administration. In addition to
these drawbacks, a recent publication shows that dGEMRIC
outcomes might not only represent sGAG content of cartilage,
but may also be influenced by collagen orientation which
influences diffusion of contrast agent into the extracellular
Figure 4.  Outcomes of KOOS and NRS questionnaires at baseline and follow-up.  Bar graphs showing the KOOS subscales
and NRS pain at baseline (light blue box) and at follow-up, 14 weeks after HA injections (dark blue box). The bar represents the
mean and the whiskers represent the 95% confidence interval for the mean. HA: hyaluronic acid injections. ADL: activities of daily
living, sports: sport and function, and QoL: knee-related quality of life. *: p-values adjusted using Holm’s method <0.05.
doi: 10.1371/journal.pone.0079785.g004
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matrix of the cartilage [56] and therefore concluded that
dGEMRIC may not be considered sGAG specific. Despite
these shortcomings of dGEMRIC, the technique is still
considered the best tool available that provides a quantitative
measure for cartilage sGAG content in human knee joints.
Finally, the timing of the follow-up measurement in our study
could be an explanation why dGEMRIC T1 relaxation times did
not improve after viscosupplementation. It may be that the
follow-up measurement was either too early or too late after
viscosupplementation to detect any changes in cartilage sGAG
content caused by the treatment. We chose a 14 weeks follow-
up period after viscosupplementation based on a Cochrane
review on the efficacy of HA injections as treatment in knee OA
[7], in which the maximum clinical benefit of HA injections was
reached between 5 and 14 weeks after treatment. It is known
that sGAGs are being synthesized within days instead of
weeks [57]. Moreover, previous in vivo animal research has
shown that newly synthesized sGAGs have a turnover time
over 100 days [58,59] and therefore should be still detectable
14 weeks after viscosupplementation. Therefore, we
considered our follow-up period of 14 weeks appropriate in
relation to our hypothesis. Future research with earlier or
extended follow-up measurements might give better insight
whether our findings are consistent over time.
In contrast to the results of dGEMRIC, all KOOS subscales
(‘pain’, ‘symptoms’, ‘daily activities’, ‘sports’ and ’quality of life’)
and the NRS for pain improved significantly 14 weeks after
viscosupplementation with HA. These results are in agreement
with aforementioned studies [6,7] in which a significant
reduction in patient complaints was observed after HA
injections. The relief in patient complaints without an
improvement in cartilage sGAG content might be due to the
placebo effect of viscosupplementation [50]. However, the
clinical efficacy of HA may also be attributed to a positive effect
of viscosupplementation on the viscoelastic properties of the
synovial fluid [5] and a positive effect on the synovial
membrane, which has been observed histologically in previous
clinical studies in OA patients [60-62]. It has been suggested in
previous work that this might have anti-inflammatory effects
causing less synovitis and therefore less knee complaints since
pain and synovitis were recently shown to be closely related in
OA patients [63-65].
In conclusion, the results of this study confirm earlier findings
reported in the literature, showing a persisting efficacy of
viscosupplementation on symptomatic outcome measures of
early-stage OA knees 14 weeks after treatment. Outcomes of
dGEMRIC, however, did not change after
viscosupplementation, indicating no change in cartilage
structural composition as an explanation for the improvement
of clinical symptoms.
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